India's Cadila Healthcare said it has bought out the shares of Bharat Serums and Vaccines to gain total control of their 10-year-old joint venture, Zydus BSV Pharma, and make it a wholly owned subsidiary.
The exchange of niceties and promises of softness in recent meetings with India counterparts notwithstanding, the U.S. FDA continues to take harsh action against India drug-production plants. The latest is a ban on imports from two more Ipca Laboratories plants.
Glenmark's marketing of a couple of diabetes generics in the United States continues to fluctuate like a yo-yo on a string. Now the India drugmaker can return the drugs to market until April 28.
After issuing an import alert last year for an IPCA Laboratories API plant in India where employees had been falsifying drug testing results and deleting failed tests, the FDA began looking at its operations further upstream and has now banned products from two of IPCA's finished product facilities.
In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.
India regulators are mulling whether to invoke emergency procedures and order drugmakers to produce and distribute more human albumin, which has been in short supply for nearly a year.
Wockhardt's U.S. affiliate must face a mass of suits in a state court over its generic version of the acid reflux drug Reglan (metoclopramide), developed by Wyeth before the firm was bought by Pfizer.
India intends to establish 10 drug manufacturing clusters in the country and invest in infrastructure there like water, power and sewer treatment facilities that drugmakers can share in an effort to cut costs.
It has been more than a year and a half since the FDA issued a warning letter for two plants in India owned by Aarti Drugs. But the drugmaker has yet to meet FDA expectations and so the agency has now put them on an import alert, banning them from shipping products to the U.S.
India's government has threatened to place restrictions on imports of nonessential items, including pharmaceuticals, from China if it does not ease some of its "protectionist tendencies" toward India products.